News Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

End-of-day quote Nyse Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
2.02 ^USD	-3.35%		-4.04%	-8.18%

Apr. 03	Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	CI
Mar. 28	Can-Fite Biopharma Ltd. Announces Clinical Update	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL	Apr. 26	AQ
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	Apr. 25	BU
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	Apr. 16	AQ
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	Apr. 15	BU
Can Fite BioPharma : Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	Apr. 15	PU
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	Apr. 03	PU
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	Apr. 03	BU
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	Apr. 03	CI
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV	Apr. 01	NE
Can Fite BioPharma : 20F FOR 2023	Mar. 28	PU
Can-Fite Biopharma Ltd. Announces Clinical Update	Mar. 28	CI
Can-Fite Reports 2023 Financial Results and Clinical Update	Mar. 28	BU
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	Mar. 11	CI
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	Mar. 11	BU
CAN-FITE BROADENS ITS STRONG INTELLECTUAL PROPERTY FOR NASH, RECEIVED PATENT ALLOWANCE IN CANADA	Feb. 29	AQ
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	Feb. 28	CI
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	Feb. 28	BU
CAN-FITE, TOP SCIENTIFIC JOURNAL PUBLISHED POSITIVE DATA FROM THE COMFORT-1 PHASE III PSORIASIS STUDY	Jan. 30	AQ
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	Jan. 30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

Summary

Filters